Initiation of rivaroxaban in patients with nonvalvular atrial fibrillation at the primary care level: The Swiss Therapy in Atrial Fibrillation for the Regulation of Coagulation (STAR) Study

被引:15
|
作者
Engelberger, Rolf P. [1 ,2 ,3 ]
Noll, Georg [4 ]
Schmidt, Dominique
Alatri, Adriano [1 ]
Frei, Benedikt
Kaiser, Walter E. [5 ]
Kucher, Nils [2 ,3 ,6 ]
机构
[1] CHU Vaudois, Div Angiol, CH-1011 Lausanne, Switzerland
[2] Inselspital Bern, Univ Hosp, Swiss Cardiovasc Ctr, Clin Angiol, Bern, Switzerland
[3] Univ Bern, CH-3012 Bern, Switzerland
[4] Klin Hirslanden, HerzKlin, Zurich, Switzerland
[5] DocWorld AG, Menzingen, Switzerland
[6] Univ Hosp, Inselspital, Swiss Cardiovasc Ctr, Clin Cardiol, Bern, Switzerland
关键词
Atrial fibrillation; Primary care; Rivaroxaban; Stroke prevention; Treatment satisfaction; STROKE PREVENTION; ANTITHROMBOTIC THERAPY; TREATMENT SATISFACTION; ORAL ANTICOAGULATION; WARFARIN; RISK; DABIGATRAN; ADHERENCE; MANAGEMENT; PHYSICIANS;
D O I
10.1016/j.ejim.2015.04.014
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Rivaroxaban has become an alternative to vitamin-K antagonists (VKA) for stroke prevention in non-valvular atrial fibrillation (AF) patients due to its favourable risk-benefit profile in the restrictive setting of a large randomized trial. However in the primary care setting, physician's motivation to begin with rivaroxaban, treatment satisfaction and the clinical event rate after the initiation of rivaroxaban are not known. Methods: Prospective data collection by 115 primary care physicians in Switzerland on consecutive nonvalvular AF patients with newly established rivaroxaban anticoagulation with 3-month follow-up. Results: We enrolled 537 patients (73 +/- 11 years, 57% men) with mean CHADS2 and HAS-BLED-scores of 2.2 +/- 1.3 and 2.4 +/- 1.1, respectively: 301(56%) were switched from VKA to rivaroxaban (STR-group) and 236(44%) were VKA-naive (VN-group). Absence of routine coagulation monitoring (68%) and fixed-dose once-daily treatment (58%) were the most frequent criteria for physicians to initiate rivaroxaban. In the STR-group, patient's satisfaction increased from 3.6 +/- 1.4 under VKA to 5.5 +/- 0.8 points (P < 0.001), and overall physician satisfaction from 3.9 +/- 1.3 to 5.4 +/- 0.9 points (P < 0.001) at 3months of rivaroxaban therapy (score from 1 to 6 with higher scores indicating greater satisfaction). In the VN-group, both patient's (5.4 +/- 0.9) and physician's satisfaction (5.5 +/- 0.7) at follow-up were comparable to the STR-group. During follow-up, 1(0.19%; 95% CI, 0.01-1.03%) ischemic stroke, 2(0.37%; 95% CI, 0.05-1.34%) major non-fatal bleeding and 11(2.05%; 95% CI, 1.03-3.64%) minor bleeding complications occurred. Rivaroxaban was stopped in 30(5.6%) patients, with side effects being the most frequent reason. Conclusion: Initiation of rivaroxaban for patients with nonvalvular AF by primary care physicians was associated with a low clinical event rate and with high overall patient's and physician's satisfaction. (C) 2015 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:508 / 514
页数:7
相关论文
共 50 条
  • [41] Discontinuation and primary care visits in nonvalvular atrial fibrillation patients treated with apixaban or warfarin
    Ramagopalan, Sreeram V.
    Graham, Sophie
    Carroll, Robert
    Raluy-Callado, Mireia
    Nordstrom, Beth L.
    Donaldson, Robert
    Colby, Chris
    Mehmud, Faisal
    Alikhan, Raza
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2019, 8 (06) : 371 - 379
  • [42] APPROPRIATENESS OF ANTICOAGULATION THERAPY FOR PRIMARY CARE PATIENTS WITH ATRIAL FIBRILLATION
    Martinez, Kathryn A.
    Eckman, Mark H.
    Rothberg, Michael B.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2020, 35 (SUPPL 1) : S17 - S17
  • [43] Using primary care data to assess comparative effectiveness and safety of apixaban and rivaroxaban in patients with nonvalvular atrial fibrillation in the UK: an observational cohort study
    Jaksa, Ashley
    Gibbs, Liza
    Kent, Seamus
    Rowark, Shaun
    Duffield, Stephen
    Sharma, Manuj
    Kincaid, Lynne
    Ali, Ayad K.
    Patrick, Amanda R.
    Govil, Priya
    Jonsson, Pall
    Gatto, Nicolle
    BMJ OPEN, 2022, 12 (10):
  • [44] Effectiveness and safety of rivaroxaban in a cohort of 142 patients with nonvalvular atrial fibrillation treated with rivaroxaban for the prevention of stroke
    Jose Cerezo-Manchado, Juan
    Navarro-Almenzar, Begona
    Elvira Ruiz, Gines
    Garcia-Candel, Faustino
    Flores Blanco, Pedro
    Caro-Martinez, Cesar
    Manzano-Fernandez, Sergio
    Garcia-Iniesta, Natalia
    Sanchez-Garcia, Javier
    Cabanas-Perianes, Valentin
    Moraleda Jimenez, Jose Maria
    FUTURE CARDIOLOGY, 2018, 14 (03) : 31 - 37
  • [45] Left atrial diameter in nonvalvular atrial fibrillation: An echocardiographic study
    Dittrich, HC
    Pearce, LA
    Asinger, RW
    McBride, R
    Webel, R
    Zabalgoitia, M
    Pennock, GD
    Safford, RE
    Rothbart, RM
    Halperin, JL
    Hart, RG
    AMERICAN HEART JOURNAL, 1999, 137 (03) : 494 - 499
  • [46] Trough Concentration Deficiency of Rivaroxaban in Patients With Nonvalvular Atrial Fibrillation Leading to Thromboembolism Events
    Gao, Hongjin
    Li, Yumei
    Sun, Hong
    Huang, Xiufang
    Chen, Hui
    Lin, Wei
    Chen, Min
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2022, 80 (06) : 869 - 876
  • [47] Anticoagulation Control in Patients With Nonvalvular Atrial Fibrillation Attended at Primary Care Centers in Spain: The PAULA Study
    Barrios, Vivencio
    Escobar, Carlos
    Prieto, Luis
    Osorio, Genoveva
    Polo, Jose
    Maria Lobos, Jose
    Vargas, Diego
    Garcia, Nicolas
    REVISTA ESPANOLA DE CARDIOLOGIA, 2015, 68 (09): : 769 - 776
  • [48] MAJOR BLEEDING AMONG RIVAROXABAN USERS WITH NONVALVULAR ATRIAL FIBRILLATION AND DIABETES
    Patel, Manesh R.
    Tamayo, Sally
    Yuan, Zhong
    Sicignano, Nicholas
    Hopf, Kathleen
    Peacock, Frank
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 67 (13) : 733 - 733
  • [49] Influence of Polypharmacy on the Effectiveness and Safety of Rivaroxaban versus Warfarin in Patients With Nonvalvular Atrial Fibrillation
    Coleman, Craig, I
    Martinez, Brandon K.
    Bunz, Thomas J.
    Eriksson, Daniel
    Meinecke, Anna-Katharina
    Sood, Nitesh
    Baker, William L.
    CIRCULATION, 2018, 138
  • [50] Influence of Polypharmacy on the Effectiveness and Safety of Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation
    Martinez, Brandon K.
    Baker, William L.
    Sood, Nitesh A.
    Bunz, Thomas J.
    Meinecke, Anna-Katharina
    Eriksson, Daniel
    Coleman, Craig, I
    PHARMACOTHERAPY, 2019, 39 (02): : 196 - 203